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Abstract
Coagulation	as	a	process	is	interpreted	as	a	mechanism	for	reducing	excessive	blood	loss	through	the
generation	of	a	gel-like	clot	local	to	the	site	of	injury.	The	process	involves	the	activation,	adhesion
(see	Integrins),	degranulation	and	aggregation	of	platelets,	as	well	as	proteins	circulating	in	the
plasma.	The	coagulation	cascade	involves	multiple	proteins	being	converted	to	more	active	forms
from	less	active	precursors	(for	example,	prothrombin	[Factor	II]	is	converted	to	thrombin	[Factor
IIa]),	typically	through	proteolysis	(see	Proteases).	Listed	here	are	the	components	of	the	coagulation
cascade	targeted	by	agents	in	current	clinical	usage	or	at	an	advanced	level	of	development.
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